HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Walter, N. Articles by King, T. E. Search for Related Content PubMed PubMed Citation Articles by Walter, N. Articles by King, T. E., Jr.

Current Perspectives on the Treatment of Idiopathic Pulmonary Fibrosis

San Francisco General Hospital, San Francisco, California

Correspondence and requests for reprints should be addressed to Talmadge E. King, Jr., M.D., San Francisco General Hospital, 1001 Potrero Avenue, Room 5H22, San Francisco, CA 94110. E-mail: tking{at}medsfgh.ucsf.edu

ABSTRACT

The clinical course of idiopathic pulmonary fibrosis (IPF) is variable; however, the long-term survival in IPF is poor. Prednisone has been the mainstay of therapy since its release for clinical use in 1948. Recently, prednisone combined with azathioprine or cyclophosphamide has been used. A number of other drug combinations have been tried with prednisone (e.g., methotrexate, colchicine, penicillamine, or cyclosporine) but have failed or are not well tolerated by the patient. Few high quality, prospective, controlled clinical trials have been performed. Thus, there is no good evidence to support the routine use of any specific therapy in the management of IPF. Additional large clinical trials are needed to confirm the potential usefulness of the newer agents (e.g., IFN-1b, pirfenidone, N-acetylcysteine, coumadin, bosentan, or etanercept). This article examines the body of evidence supporting the current therapies and reviews the newer agents being tested in patients with IPF.

Key Words: clinical trials • drugs • idiopathic pulmonary fibrosis • interstitial lung diseases • lung transplant • treatment • usual interstitial pneumonia

This article has been cited by other articles:

				T. Kisseleva and D. A. Brenner Fibrogenesis of Parenchymal Organs Proceedings of the ATS, April 15, 2008; 5(3): 338 - 342. [Abstract] [Full Text] [PDF]

				P. Rogliani, M. Mura, M. Assunta Porretta, and C. Saltini Review: New perspectives in the treatment of idiopathic pulmonary fibrosis Therapeutic Advances in Respiratory Disease, April 1, 2008; 2(2): 75 - 93. [Abstract] [PDF]

				Y. Kabuyama, K. Oshima, T. Kitamura, M. Homma, J. Yamaki, M. Munakata, and Y. Homma Involvement of selenoprotein P in the regulation of redox balance and myofibroblast viability in idiopathic pulmonary fibrosis. Genes Cells, November 1, 2007; 12(11): 1235 - 1244. [Abstract] [Full Text] [PDF]

				C. J. Scotton and R. C. Chambers Molecular Targets in Pulmonary Fibrosis: The Myofibroblast in Focus Chest, October 1, 2007; 132(4): 1311 - 1321. [Abstract] [Full Text] [PDF]

				D. Pilling, D. Roife, M. Wang, S. D. Ronkainen, J. R. Crawford, E. L. Travis, and R. H. Gomer Reduction of Bleomycin-Induced Pulmonary Fibrosis by Serum Amyloid P J. Immunol., September 15, 2007; 179(6): 4035 - 4044. [Abstract] [Full Text] [PDF]

				M. Alakhras, P. A. Decker, H. F. Nadrous, M. Collazo-Clavell, and J. H. Ryu Body Mass Index and Mortality in Patients With Idiopathic Pulmonary Fibrosis Chest, May 1, 2007; 131(5): 1448 - 1453. [Abstract] [Full Text] [PDF]

				D. S. Kim, H. R. Collard, and T. E. King Jr. Classification and natural history of the idiopathic interstitial pneumonias. Proceedings of the ATS, January 1, 2006; 3(4): 285 - 292. [Abstract] [Full Text] [PDF]